Mounjaro vs Ozempic

Drug comparison

Last updated 2026-05-28 15:46 UTC

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both injectable medications for type 2 diabetes, made by Eli Lilly and Novo Nordisk respectively. Ozempic is also approved to reduce cardiovascular risk and treat chronic kidney disease, while Mounjaro is not. Both are given as weekly shots under the skin, but they contain different active ingredients.

AI summary of the sources below.

	Mounjaro	Ozempic
Active ingredient	tirzepatide	semaglutide
Manufacturer	eli-lilly	novo-nordisk
Route	subcutaneous injection	subcutaneous injection
FDA-approved for	type 2 diabetes	type 2 diabetes, cardiovascular risk reduction, chronic kidney disease
Label updated	2026-04-22	2026-01-30

Compare full details on the Mounjaro and Ozempic pages.